Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study

T.A.C. de Vries, M.E.W. Hemels, F. Cools, H.J.G.M. Crijns, L. Yperzeele, P. Vanacker, I. Blankoff, P. Lancellotti, G.H. Mairesse, A. de Veer, R.C. Arroyo, E. Catez, M. de Pauw, T. Vanassche, C. de Asmundis, P. Kirchhof, R. De Caterina, J.R. de Groot, P.r.i.n.c.i.p.a.l. ETNA-AF-Europe, ETNA-AF-Europe principal investigators from Belgium and the Netherlands

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)158-167
Number of pages10
JournalNetherlands Heart Journal
Volume29
Issue number3
DOIs
Publication statusPublished - 1 Mar 2021

Keywords

  • anticoagulants
  • clinical trial
  • haemorrhage
  • k oral anticoagulants
  • management
  • off-label use
  • phase iv
  • routine clinical-practice
  • stroke
  • thromboembolism
  • trends
  • warfarin
  • Anticoagulants
  • Stroke
  • MANAGEMENT
  • phase IV
  • TRENDS
  • ROUTINE CLINICAL-PRACTICE
  • Off-label use
  • WARFARIN
  • Clinical trial
  • Haemorrhage
  • Thromboembolism
  • K ORAL ANTICOAGULANTS

Cite this